Enquirer Consulting Group

Reachable Buyer Map

Prepared for Orayb Akeel · MS Pharma · August 2026
A regional pharmaceutical group of this size has two entirely separate buyers, and in this market they are usually served by one channel. One sits overseas: the business development director at a company that owns a product and has no route into the Middle East and North Africa. The other sits inside the region: the tender committee, the formulary chair, the hospital pharmacy director. This map covers where each of them sits, who signs, and roughly how many there are. It describes the market rather than your business, and there is nothing to buy at the end of it.
European specialty and generic companies without a regional route
The largest partnering pool and the one that behaves most like a normal sales market. A company holds an approved product, a small international team, and no entity anywhere between Casablanca and Muscat. The decision to appoint a regional partner is made by two or three named people and is revisited whenever a product loses exclusivity somewhere else.
Who signs: head of international markets, business development or out-licensing director, regional general manager, and the commercial lead on the product itself.
3,500 to 5,000
pharmaceutical manufacturing enterprises registered across the EU; the layer holding a portfolio and no regional presence is a fraction of that and is identified company by company
Indian and South Asian export manufacturers
A different motive and a different conversation. These companies are not looking for a commercial partner so much as a registration route and a manufacturing base that shortens approval timelines and satisfies local content expectations. The relationship starts on regulatory grounds and becomes commercial afterwards, which reverses the usual order.
Who signs: head of international business, regulatory affairs director for emerging markets, export marketing manager, and the promoter or managing director on anything structural.
Roughly 2,500 to 3,500
formulation manufacturers across India; the export-oriented layer holding international approvals is a subset and is worked one at a time
Companies needing sterile injectable and cytotoxic capacity
The scarcest capability in the market and the one with the least visible demand. Nobody publishes that they are short of fill and finish capacity for a cytotoxic line. The signal arrives instead as a launch date, a filing, a plant closure or a supply notice, which means the segment is read rather than looked up.
Who signs: head of external manufacturing, VP of supply chain, chief technical officer, and the CMC lead on the specific product.
No public register
demand for contract capacity is not enumerated anywhere; it is inferred from filings, launches and supply notices, then approached by name
Institutional and tender buyers across the Gulf
Narrow, concentrated and almost entirely name-based. A small number of national purchasing bodies, military and security medical services, and group formulary committees decide what a very large volume of the region buys. Long cycles, published calendars, and a buying group that barely changes from year to year, which makes it the most knowable segment on this page.
Who signs: tender committee chair, national procurement director, group formulary chair, hospital pharmacy director, head of supply at the ministry level.
Counted in dozens
national and group purchasing bodies across the Gulf states; the layer beneath them is thousands of prescribers, but the buying decision is not made there
Emerging North American specialty and biotech companies
Small companies with one or two assets, a US or European approval, and no plan at all for markets outside their home region. They are the least contested partnering pool because most regional groups wait for these companies to become large enough to notice. Reached early, the conversation is about a territory nobody else has asked for yet.
Who signs: chief business officer, VP of corporate development, head of commercial, and frequently the founder or chief executive directly.
2,000 to 3,000
US biopharmaceutical companies; the subset with an approved or near-approved asset and no ex-US strategy is smaller again and moves as products progress

Where the openings are

1
Partnering demand has no directory, so it defaults to whoever attends. A company looking for a regional partner finds one at a licensing convention, through a bank, or through somebody who used to work there. Every company that does not attend, and there are far more of those, stays unreached indefinitely. Reaching heads of international markets across Europe, India and North America on a schedule is the only route that does not depend on the calendar of a trade show.
2
The buyer is a role that moves, and the move is the opening. Head of international markets and regional business development are seats that turn over regularly, and a new occupant reopens the partner question almost immediately. A channel built on named roles catches that within weeks. A relationship built on one person does not survive their departure, and usually nobody finds out for a year.
3
Two sales sit inside one company and share almost nothing. Licensing a product in is an outbound business development sale to a company on another continent. Winning a tender is an institutional sale to a committee half an hour away. Different roles, different language, different cycles, different evidence. One channel almost always ends up serving whichever of the two is louder that quarter, and it is rarely the one with the longer payoff.
Built from public market data, counts banded deliberately. Company counts come from national and regional manufacturing registers and describe registered enterprises rather than active partnering candidates, so they mark the outer edge of each pool rather than the working list. Contract manufacturing demand and the institutional buying layer are not published anywhere and are described rather than counted.
ENQUIRER CONSULTING GROUP
enquirerconsulting.com